HRP20151165T1 - Inhibitori apoptoze i njihove uporabe - Google Patents
Inhibitori apoptoze i njihove uporabe Download PDFInfo
- Publication number
- HRP20151165T1 HRP20151165T1 HRP20151165TT HRP20151165T HRP20151165T1 HR P20151165 T1 HRP20151165 T1 HR P20151165T1 HR P20151165T T HRP20151165T T HR P20151165TT HR P20151165 T HRP20151165 T HR P20151165T HR P20151165 T1 HRP20151165 T1 HR P20151165T1
- Authority
- HR
- Croatia
- Prior art keywords
- peptide
- conjugate
- pharmaceutical composition
- peptidomimetic
- ischemia
- Prior art date
Links
- 230000006907 apoptotic process Effects 0.000 title claims 3
- 239000003112 inhibitor Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 239000000816 peptidomimetic Substances 0.000 claims 9
- 241001465754 Metazoa Species 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims 3
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 208000028867 ischemia Diseases 0.000 claims 3
- 229930105110 Cyclosporin A Natural products 0.000 claims 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 2
- 108010036949 Cyclosporine Proteins 0.000 claims 2
- 101150077031 DAXX gene Proteins 0.000 claims 2
- 102100028559 Death domain-associated protein 6 Human genes 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 229960001265 ciclosporin Drugs 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 206010009895 Colitis ischaemic Diseases 0.000 claims 1
- 206010022680 Intestinal ischaemia Diseases 0.000 claims 1
- 208000004535 Mesenteric Ischemia Diseases 0.000 claims 1
- 206010063897 Renal ischaemia Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 206010000891 acute myocardial infarction Diseases 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000008222 ischemic colitis Diseases 0.000 claims 1
- 201000002818 limb ischemia Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Marine Sciences & Fisheries (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (17)
1. Peptid koji se sastoji od:
fragmenta od 16, 17, 18, 19, 20, 21, 22, 23 ili 24 poredanih aminokiselinskih ostataka DAXX proteina identifikacijskog broja slijeda SEQ ID NO: 1, pri čemu navedeni fragment obuhvaća aminokiselinski slijed koji predvodi SEQ ID NO: 5, pri čemu je navedeni peptid sposoban inhibirati apoptozu stanice.
2. Peptid u skladu s patentnim zahtjevom 1, pri čemu je navedeni peptid fragment DAXX proteina koji se sastoji od aminokiselinskog slijeda predvodnika u SEQ ID NO: 5 ili bilo kojeg od SEQ ID NO: 17-44.
3. Peptidomimetik peptida u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2.
4. Konjugat koji sadrži peptid u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2 ili peptidomimetik u skladu s patentnim zahtjevom 3 povezan s peptidom koji penetrira u stanicu.
5. Konjugat u skladu s patentnim zahtjevom 4, pri čemu je navedeni peptid ili peptidomimetik putem poveznika povezan s peptidom koji penetrira u stanicu.
6. Konjugat u skladu s patentnim zahtjevom 4 ili patentnim zahtjevom 5, pri čemu je navedeni peptid koji penetrira u stanicu odabran iz grupe koja se sastoji od Tat, RXR, Bpep i Pip2b.
7. Konjugat u skladu s patentnim zahtjevom 6, pri čemu se navedeni konjugat sastoji od aminokiselinskog slijeda predvodnika iz SEQ ID NO: 58, ili SEQ ID NO: 61,
8. Farmaceutski sastav koji sadrži učinkovitu količinu barem jednog peptida u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, ili barem jedan peptidomimetik u skladu s patentnim zahtjevom 3, ili barem jedan konjugat u skladu s bilo kojim od patentnih zahtjeva 4-7 i barem jedan farmaceutski prihvatljivi nosač ili ekscipijens.
9. Farmaceutski sastav iz patentnog zahtjeva 8 nadalje obuhvaća barem jedan dodatni biološki aktivan agens.
10. Farmaceutski sastav u skladu s patentnim zahtjevom 9, pri čemu je navedeni barem jedan dodatni biološki aktivan agens odabran iz grupe koja se sastoji od ciklosporina A, BH4 i njihovih kombinacija.
11. Peptid u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2 ili peptidomimetik u skladu s patentnim zahtjevom 3, ili konjugat u skladu s bilo kojim od patentnih zahtjeva 4-7 ili farmaceutski sastav iz bilo kojeg od patentnih zahtjeva 8-10, za uporabu u metodi liječenja ljudskog ili životinjskog tijela.
12. Peptid u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2 ili peptidomimetik u skladu s patentnim zahtjevom 3, ili konjugat u skladu s bilo kojim od patentnih zahtjeva 4-7 ili farmaceutski sastav iz bilo kojeg od patentnih zahtjeva 8-10, za uporabu u metodi za inhibiranje apptoze stanice u ljudskom ili životinjskom tijelu.
13. Peptid u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2 ili peptidomimetik u skladu s patentnim zahtjevom 3, ili konjugat u skladu s bilo kojim od patentnih zahtjeva 4-7 ili farmaceutski sastav iz bilo kojeg od patentnih zahtjeva 8-10, za uporabu u metodi za liječenje akutnog infarkta miokarda, cerebralnog infarkta, transplantacije organa, srčanih intervencija, ili akutnih cirkulacijskih perturbacija, u ljudskom ili životinjskom tijelu.
14. Peptid u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2 ili peptidomimetik u skladu s patentnim zahtjevom 3, ili konjugat u skladu s bilo kojim od patentnih zahtjeva 4-7 ili farmaceutski sastav iz bilo kojeg od patentnih zahtjeva 8-10, za uporabu u metodi za liječenje ishemije u ljudskom ili životinjskom tijelu.
15. Peptid, ili derivat, ili konjugat ili farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 14, pri čemu je ishemija srčana ishemija, bubrežna ishemija, ishemijski kolitis, mezenterijska ishemija, moždana ishemija, ishemija uda ili ishemija kože.
16. Peptid u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2 ili peptidomimetik u skladu s patentnim zahtjevom 3, ili konjugat u skladu s bilo kojim od patentnih zahtjeva 4-7 ili farmaceutski sastav iz bilo kojeg od patentnih zahtjeva 8-10, za uporabu u metodi za liječenje reperfuzijske ozljede u ljudskom ili životinjskom tijelu.
17. Peptid, ili derivat, ili konjugat ili farmaceutski sastav za uporabu u skladu s bilo kojim od patentnih zahtjeva 12-16, pri čemu navedena metoda također obuhvaća korak davanja ciklosporina A i/ili BH4 navedenom ljudskom ili životinjskom tijelu.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2010/003158 WO2012066376A1 (en) | 2010-11-18 | 2010-11-18 | Inhibitors of apoptosis and uses thereof |
| EP11785011.5A EP2640739B1 (en) | 2010-11-18 | 2011-11-17 | Inhibitors of apoptosis and uses thereof |
| PCT/EP2011/070404 WO2012066103A2 (en) | 2010-11-18 | 2011-11-17 | Inhibitors of apoptosis and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20151165T1 true HRP20151165T1 (hr) | 2015-12-18 |
Family
ID=43880951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20151165TT HRP20151165T1 (hr) | 2010-11-18 | 2015-11-02 | Inhibitori apoptoze i njihove uporabe |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US9814758B2 (hr) |
| EP (2) | EP2640739B1 (hr) |
| JP (1) | JP6204828B2 (hr) |
| KR (2) | KR102017645B1 (hr) |
| CN (2) | CN103403023B (hr) |
| AU (1) | AU2011331103B2 (hr) |
| BR (1) | BR112013012362A2 (hr) |
| CA (2) | CA2816827C (hr) |
| CL (1) | CL2013001411A1 (hr) |
| CO (1) | CO6700879A2 (hr) |
| CR (1) | CR20130190A (hr) |
| CY (1) | CY1118022T1 (hr) |
| DK (1) | DK2640739T3 (hr) |
| EA (1) | EA027336B1 (hr) |
| ES (2) | ES2553770T3 (hr) |
| GE (1) | GEP201606514B (hr) |
| GT (1) | GT201300117A (hr) |
| HK (1) | HK1184791A1 (hr) |
| HR (1) | HRP20151165T1 (hr) |
| HU (1) | HUE026150T2 (hr) |
| IL (2) | IL226005B (hr) |
| MA (1) | MA34670B1 (hr) |
| ME (1) | ME02291B (hr) |
| MX (1) | MX345594B (hr) |
| MY (1) | MY170604A (hr) |
| NI (1) | NI201300045A (hr) |
| NZ (1) | NZ610620A (hr) |
| PL (1) | PL2640739T3 (hr) |
| PT (1) | PT2640739E (hr) |
| RS (1) | RS54422B1 (hr) |
| RU (1) | RU2582247C2 (hr) |
| SG (1) | SG190681A1 (hr) |
| SI (1) | SI2640739T1 (hr) |
| UA (1) | UA112420C2 (hr) |
| WO (2) | WO2012066376A1 (hr) |
| ZA (1) | ZA201303042B (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10632237B2 (en) | 2006-10-09 | 2020-04-28 | Minnetronix, Inc. | Tangential flow filter system for the filtration of materials from biologic fluids |
| WO2012066376A1 (en) * | 2010-11-18 | 2012-05-24 | Centre National De La Recherche Scientifique - Cnrs - | Inhibitors of apoptosis and uses thereof |
| GB201314610D0 (en) * | 2013-08-15 | 2013-10-02 | Blueberry Therapeutics Ltd | Compounds and their uses |
| CN103585618B (zh) * | 2013-10-31 | 2016-04-06 | 中山大学 | 端粒结合蛋白daxx在制备肿瘤细胞调控剂中的应用 |
| WO2017082707A1 (ko) * | 2015-11-13 | 2017-05-18 | 한양대학교 산학협력단 | 비강 투여를 통한 뇌졸중 치료용 조성물 |
| WO2019195693A1 (en) * | 2018-04-05 | 2019-10-10 | University Of Florida Research Foundation | Polypeptide inhibitor of de novo lipogenesis in cancer cells |
| CN108753820A (zh) * | 2018-06-07 | 2018-11-06 | 嘉兴学院 | Daxx蛋白通过激活erk信号通路促进卵巢癌腹水细胞增殖和转移 |
| CN112679595B (zh) * | 2020-04-10 | 2022-11-01 | 南京市儿童医院 | 脑源肽或融合肽在新生儿缺氧缺血性脑损伤药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6159731A (en) * | 1997-02-12 | 2000-12-12 | Massachusetts Institute Of Technology | Daxx, a Fas-binding protein that activates JNK and apoptosis |
| WO2002065986A2 (en) * | 2001-02-16 | 2002-08-29 | Cellgate, Inc. | Transporters comprising spaced arginine moieties |
| RU2328273C2 (ru) * | 2001-12-19 | 2008-07-10 | Рисерч Дивелопмент Фаундейшн | Липосомальная доставка соединений, основанных на витамине е |
| KR100597615B1 (ko) * | 2004-05-07 | 2006-07-10 | 주식회사 동부한농 | 인간 ＮＨＥ1 이온채널 단백질 결합제로서의 인간Ｄａｘｘ 단백질 및 그의 단편 |
| WO2010006177A2 (en) * | 2008-07-10 | 2010-01-14 | Dana-Farber Cancer Institute, Inc. | Muc1, caspase-8,and ded-containing proteins |
| WO2012066376A1 (en) * | 2010-11-18 | 2012-05-24 | Centre National De La Recherche Scientifique - Cnrs - | Inhibitors of apoptosis and uses thereof |
-
2010
- 2010-11-18 WO PCT/IB2010/003158 patent/WO2012066376A1/en active Application Filing
-
2011
- 2011-11-17 CA CA2816827A patent/CA2816827C/en active Active
- 2011-11-17 NZ NZ610620A patent/NZ610620A/en not_active IP Right Cessation
- 2011-11-17 RU RU2013127565/10A patent/RU2582247C2/ru not_active IP Right Cessation
- 2011-11-17 JP JP2013539274A patent/JP6204828B2/ja active Active
- 2011-11-17 ME MEP-2015-184A patent/ME02291B/me unknown
- 2011-11-17 US US13/885,956 patent/US9814758B2/en active Active
- 2011-11-17 KR KR1020187030658A patent/KR102017645B1/ko active IP Right Grant
- 2011-11-17 WO PCT/EP2011/070404 patent/WO2012066103A2/en active Application Filing
- 2011-11-17 EA EA201300592A patent/EA027336B1/ru not_active IP Right Cessation
- 2011-11-17 ES ES11785011.5T patent/ES2553770T3/es active Active
- 2011-11-17 GE GEAP201113091A patent/GEP201606514B/en unknown
- 2011-11-17 CN CN201180055357.4A patent/CN103403023B/zh active Active
- 2011-11-17 RS RS20150753A patent/RS54422B1/en unknown
- 2011-11-17 EP EP11785011.5A patent/EP2640739B1/en active Active
- 2011-11-17 KR KR1020137015652A patent/KR101913285B1/ko active IP Right Grant
- 2011-11-17 MX MX2013005587A patent/MX345594B/es active IP Right Grant
- 2011-11-17 EP EP15182520.5A patent/EP2982685B1/en active Active
- 2011-11-17 CA CA3078178A patent/CA3078178C/en active Active
- 2011-11-17 MY MYPI2013001678A patent/MY170604A/en unknown
- 2011-11-17 DK DK11785011.5T patent/DK2640739T3/en active
- 2011-11-17 SI SI201130663T patent/SI2640739T1/sl unknown
- 2011-11-17 SG SG2013034939A patent/SG190681A1/en unknown
- 2011-11-17 BR BR112013012362A patent/BR112013012362A2/pt not_active Application Discontinuation
- 2011-11-17 AU AU2011331103A patent/AU2011331103B2/en not_active Ceased
- 2011-11-17 HU HUE11785011A patent/HUE026150T2/en unknown
- 2011-11-17 UA UAA201306150A patent/UA112420C2/uk unknown
- 2011-11-17 PT PT117850115T patent/PT2640739E/pt unknown
- 2011-11-17 PL PL11785011T patent/PL2640739T3/pl unknown
- 2011-11-17 CN CN201610579046.2A patent/CN106188271B/zh active Active
- 2011-11-17 ES ES15182520.5T patent/ES2653734T3/es active Active
-
2013
- 2013-04-25 ZA ZA2013/03042A patent/ZA201303042B/en unknown
- 2013-04-28 IL IL226005A patent/IL226005B/en active IP Right Grant
- 2013-05-02 CR CR20130190A patent/CR20130190A/es unknown
- 2013-05-08 GT GT201300117A patent/GT201300117A/es unknown
- 2013-05-14 NI NI201300045A patent/NI201300045A/es unknown
- 2013-05-15 MA MA35909A patent/MA34670B1/fr unknown
- 2013-05-16 CO CO13121197A patent/CO6700879A2/es unknown
- 2013-05-17 CL CL2013001411A patent/CL2013001411A1/es unknown
- 2013-10-25 HK HK13112062.3A patent/HK1184791A1/zh not_active IP Right Cessation
-
2015
- 2015-11-02 HR HRP20151165TT patent/HRP20151165T1/hr unknown
- 2015-11-17 CY CY20151101030T patent/CY1118022T1/el unknown
-
2018
- 2018-01-22 IL IL257069A patent/IL257069B/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20151165T1 (hr) | Inhibitori apoptoze i njihove uporabe | |
| JP2014050390A5 (hr) | ||
| AU2011272137B2 (en) | Novel peptide and use thereof | |
| KR101746787B1 (ko) | 미백, 피부 탄력, 주름 개선 및 상처치유 활성을 갖는 다기능성 피부투과 펩타이드 | |
| JP2016516023A5 (hr) | ||
| ES2640814T3 (es) | Inhibidores selectivos de caspasa y usos de los mismos | |
| KR20200022435A (ko) | 펩타이드 조성물 및 관련된 방법 | |
| Bettenworth et al. | The tripeptide KdPT protects from intestinal inflammation and maintains intestinal barrier function | |
| KR101782569B1 (ko) | 미백, 피부 탄력 및 주름 개선 활성을 갖는 다기능성 피부투과 펩타이드 | |
| US20230174582A1 (en) | Vipr2 antagonist peptide | |
| RU2537560C2 (ru) | Тетрапептид и средство, обладающее церебропротекторной и антиамнестической активностями (варианты) | |
| AR114162A1 (es) | Composición farmacéutica líquida | |
| WO2017082692A1 (ko) | 미백, 피부 탄력 및 주름 개선 활성을 갖는 다기능성 피부투과 펩타이드 | |
| RU2008125167A (ru) | Терапевтическое средство для ускоренного заживления кожи, содержащее в качестве активного ингредиента дезацил-грелин и его производные | |
| KR20210050433A (ko) | 암 세포의 증식을 억제하는 펩티드 fnin2 및 이의 용도 | |
| CN114364691B (zh) | 作为纤维化基质积累的抑制剂的肽 | |
| CN1170585C (zh) | 神经疾病的治疗剂 | |
| Altamura et al. | Cyclic glycopeptidomimetics through a versatile sugar-based scaffold |